The Efficacy of Omalizumab Therapy in Chronic Inducible Urticaria

Background: Immunoglobulin E antibody omalizumab is an effective and safe treatment option in patients with chronic urticaria and evidence is lacking in patients with chronic inducible urticaria (CindU). In this study, it was aimed to determine the efficacy of omalizumab in patients with CindU. Materials and Methods: Patients treated with omalizumab resistant to second-generation antihistamine therapy were included in the study. Demographic characteristics, duration of disease, duration of omalizumab use and comorbidities of the patients were obtained from health records. Results: We enrolled 27 patients ranging in age from 17 to 55 years, 9 patients had cholinergic, 2 aquagenic, 7 symptomatic dermographism, 4 cold, 4 pressure, 3 solar urticaria. Complete response was observed in 20 patients, partial response in 3 patients, and no response in 4 patients treated with omalizumab. Conclusion: A higher percentage of patients had a complete response with 300 mg of omalizumab treatment. Keywords: Urticaria, Inducible, Treatment